[go: up one dir, main page]

WO2001081368A3 - Blood-pressure reducing polypeptides containing vpp derived from microorganisms - Google Patents

Blood-pressure reducing polypeptides containing vpp derived from microorganisms Download PDF

Info

Publication number
WO2001081368A3
WO2001081368A3 PCT/US2001/012776 US0112776W WO0181368A3 WO 2001081368 A3 WO2001081368 A3 WO 2001081368A3 US 0112776 W US0112776 W US 0112776W WO 0181368 A3 WO0181368 A3 WO 0181368A3
Authority
WO
WIPO (PCT)
Prior art keywords
microorganisms
blood
derived
pressure reducing
polypeptides containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/012776
Other languages
French (fr)
Other versions
WO2001081368A2 (en
Inventor
Joseph M Kobzeff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monsanto Technology LLC
Original Assignee
Monsanto Technology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Technology LLC filed Critical Monsanto Technology LLC
Priority to AU2001255501A priority Critical patent/AU2001255501A1/en
Publication of WO2001081368A2 publication Critical patent/WO2001081368A2/en
Publication of WO2001081368A3 publication Critical patent/WO2001081368A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to a method of producing the anti-hypertensive tripeptide VPP. The invention also relates to pharmaceutical, nutritional, and food compositions employing VPP as the active ingredient.
PCT/US2001/012776 2000-04-21 2001-04-19 Blood-pressure reducing polypeptides containing vpp derived from microorganisms Ceased WO2001081368A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001255501A AU2001255501A1 (en) 2000-04-21 2001-04-19 Blood-pressure reducing polypeptides containing vpp derived from microorganisms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19968000P 2000-04-21 2000-04-21
US60/199,680 2000-04-21

Publications (2)

Publication Number Publication Date
WO2001081368A2 WO2001081368A2 (en) 2001-11-01
WO2001081368A3 true WO2001081368A3 (en) 2002-05-16

Family

ID=22738560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012776 Ceased WO2001081368A2 (en) 2000-04-21 2001-04-19 Blood-pressure reducing polypeptides containing vpp derived from microorganisms

Country Status (2)

Country Link
AU (1) AU2001255501A1 (en)
WO (1) WO2001081368A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI328457B (en) * 2003-03-18 2010-08-11 Suntory Holdings Ltd Angiotensin-converting enzyme inhibitory peptides
NZ552140A (en) * 2004-07-12 2009-02-28 Dsm Ip Assets Bv Blood pressure lowering protein hydrolysates
US7879804B2 (en) 2004-12-22 2011-02-01 Dsm Ip Assets B.V. Blood pressure lowering peptides in a single enzymatic step
CN101171024A (en) * 2005-04-28 2008-04-30 帝斯曼知识产权资产管理有限公司 Antihypertensive protein hydrolyzate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0583074A2 (en) * 1992-07-23 1994-02-16 The Calpis Food Industry Co., Ltd. Angiotensin converting enzyme inhibitor and method for preparing same
WO1996017054A1 (en) * 1994-12-01 1996-06-06 Oklahoma Medical Research Foundation Method and compositions for reducing cholesterol absorption
WO1996037622A1 (en) * 1995-05-24 1996-11-28 Astra Aktiebolag (Publ) A dna molecule for expression of bile salt-stimulated lipase (bssl)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0583074A2 (en) * 1992-07-23 1994-02-16 The Calpis Food Industry Co., Ltd. Angiotensin converting enzyme inhibitor and method for preparing same
WO1996017054A1 (en) * 1994-12-01 1996-06-06 Oklahoma Medical Research Foundation Method and compositions for reducing cholesterol absorption
WO1996037622A1 (en) * 1995-05-24 1996-11-28 Astra Aktiebolag (Publ) A dna molecule for expression of bile salt-stimulated lipase (bssl)

Also Published As

Publication number Publication date
AU2001255501A1 (en) 2001-11-07
WO2001081368A2 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
WO2001058412A3 (en) Extracts from residues left in the production of wine
EP2263470A3 (en) Delivery of functional ingredients
EP1293503A4 (en) Triazole derivatives
ZA200203867B (en) alpha-Amino acids compounds, a process for their preparation and pharmaceutical compositions containing them.
AP2003002916A0 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
EP2292253A3 (en) Stabilized pharmaceutical peptide compositions
WO2003086267A3 (en) Multi-phase, multi-compartment capsular system
HUP0200623A2 (en) 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors and pharmaceutical compositions containing them
PL367447A1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
WO2003014079A8 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
AU2002243005A1 (en) Vital cell preparations containing lactic acid bacterium as the active ingredient and lactic acid bacterium-containing foods
CA2368574A1 (en) Compositions for preventing and treating type i allergy
WO2003087050A3 (en) Novel perindopril salt and pharmaceutical compositions containing same
WO2002056708A3 (en) Preparation for improved dietary utilisation
CA2431998A1 (en) Flavour concentrates
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
WO2003099192A3 (en) Bis-aromatic alkanols
WO2001080873A3 (en) Thrombopoietin receptor modulating peptide
MXPA03008420A (en) Solid orally-dispersible pharmaceutical formulation.
WO2004031202A3 (en) Condensed palatinose in hydrogenated form
CA2567582A1 (en) Anti-hypertensive dietary supplement derived from salmo or oncorhynchus protein hydrolysates
AU2002241408A1 (en) Modular system of dietary supplement compositions comprising vitamins
WO2003049687A3 (en) Medicinal compositions & therapeutic methods
WO2001078682A3 (en) Sustained release drug compositions
EP1097646A3 (en) Modified milk powder composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP